Collaboration, License, Development and Commercialization Agreement By and Between Aratana Therapeutics, Inc. and Eli Lilly and Company acting on behalf of its Elanco Animal Health Division Effective as ofCommercialization Agreement • August 5th, 2016 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This Collaboration, License, Development and Commercialization Agreement , effective as of 22 April 2016 (the “Effective Date”), is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation and having its office at 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 (“Licensor”) and Eli Lilly and Company, an Indiana corporation, operating on behalf of its Elanco Animal Health division and having its office at 2500 Innovation Way, Greenfield, Indiana 46140 and its Affiliates (“Elanco”).
CO-PROMOTION AGREEMENTCo-Promotion Agreement • August 5th, 2016 • Aratana Therapeutics, Inc. • Pharmaceutical preparations
This Co-Promotion Agreement (this “Agreement”), effective as of April 22, 2016 (the “Effective Date”), is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation and having its office at 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 (“Aratana”) and Eli Lilly and Company, an Indiana corporation, operating on behalf of its Elanco Animal Health division and having its office at 2500 Innovation Way, Greenfield, Indiana 46140 and its Affiliates (“Elanco”).
